BR0317217A - Uso de derivados de ésteres de succinato para a produção de medicamentos e composição farmacêutica - Google Patents

Uso de derivados de ésteres de succinato para a produção de medicamentos e composição farmacêutica

Info

Publication number
BR0317217A
BR0317217A BR0317217-1A BR0317217A BR0317217A BR 0317217 A BR0317217 A BR 0317217A BR 0317217 A BR0317217 A BR 0317217A BR 0317217 A BR0317217 A BR 0317217A
Authority
BR
Brazil
Prior art keywords
dementia
ester derivatives
improve
memory capacity
succinate ester
Prior art date
Application number
BR0317217-1A
Other languages
English (en)
Inventor
Shengyang Huang
Yongchun Yang
Jianjun Zhang
Jiangong Shi
Mei Gao
Dan Zhang
Yafang Wang
Original Assignee
Inst Materia Medica Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Materia Medica Cams filed Critical Inst Materia Medica Cams
Publication of BR0317217A publication Critical patent/BR0317217A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE DERIVADOS DE éSTERES DE SUCCINATO PARA A PRODUçãO DE MEDICAMENTOS E COMPOSIçãO FARMACêUTICA". A presente invenção refere-se ao uso do extrato de Wangla (Coeloglossum viride (L) Hartm. Var. Bracteatum (Willd. Richter)), derivados de ésteres de succinato, de um derivado e sais farmaceuticamente aceitáveis dos mesmos, para a produção de uma preparação farmacêutica para tratamento de demência, particularmente, para tratamento da doença de Alzheimer e da demência vascular. Através de experimentos em modelos animais, foi demonstrado que os derivados de ésteres de succinato podem melhorar a capacidade de aprendizado e de memória dos ratos com demência induzida por escopolamina e por ciclohexenil imina; melhorar a capacidade de aprendizado e de memória de ratos com demência induzida por ligação permanente da carótida bilateral; e melhorar a capacidade de memória dos animais normais. Estes são vantajosos devidos a alta atividade, baixa toxicidade e pela não inibição da colinesterase.
BR0317217-1A 2002-12-31 2003-12-31 Uso de derivados de ésteres de succinato para a produção de medicamentos e composição farmacêutica BR0317217A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA021593426A CN1511520A (zh) 2002-12-31 2002-12-31 丁二酸酯衍生物治疗痴呆症的用途
PCT/CN2003/001155 WO2004058244A1 (fr) 2002-12-31 2003-12-31 Utilisation d'esters de derives succinate pour le traitement de la demence

Publications (1)

Publication Number Publication Date
BR0317217A true BR0317217A (pt) 2005-11-01

Family

ID=32661095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317217-1A BR0317217A (pt) 2002-12-31 2003-12-31 Uso de derivados de ésteres de succinato para a produção de medicamentos e composição farmacêutica

Country Status (12)

Country Link
US (1) US7557089B2 (pt)
EP (1) EP1582209B1 (pt)
JP (1) JP4880223B2 (pt)
KR (1) KR100855389B1 (pt)
CN (3) CN1511520A (pt)
AU (1) AU2003292876A1 (pt)
BR (1) BR0317217A (pt)
CA (1) CA2512187C (pt)
ES (1) ES2395725T3 (pt)
IL (1) IL169489A0 (pt)
RU (1) RU2334524C2 (pt)
WO (1) WO2004058244A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
RU2504367C1 (ru) * 2012-06-05 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности
US20150306158A1 (en) 2012-08-16 2015-10-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
CN109160928B (zh) * 2017-09-21 2020-07-21 暨南大学 辣木籽中新的酚苷类化合物及其应用
CN108690104B (zh) * 2018-05-08 2020-11-20 北京理工大学 一类葡萄糖氧基苄酯类化合物、其制备方法及其应用
CN110698531B (zh) * 2019-11-01 2020-11-03 首都医科大学附属北京中医医院 一种用于改善微循环障碍的新化合物及其制法
CN110787172B (zh) * 2019-12-13 2022-07-01 中央民族大学 洛罗兰糖苷在制备防治糖尿病的药物中的应用以及一种防治糖尿病的药物
CN113730425B (zh) * 2021-09-06 2023-05-23 北京斯利安健康科技有限公司 含叶酸的组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104253C (zh) * 1999-05-25 2003-04-02 青海省老年医学研究所 一种强身健体、增强机体免疫功能的药

Also Published As

Publication number Publication date
CA2512187C (en) 2011-03-01
KR100855389B1 (ko) 2008-09-04
CN101015648A (zh) 2007-08-15
ES2395725T3 (es) 2013-02-14
US7557089B2 (en) 2009-07-07
WO2004058244A1 (fr) 2004-07-15
CN1511520A (zh) 2004-07-14
RU2334524C2 (ru) 2008-09-27
US20060281692A1 (en) 2006-12-14
RU2005124275A (ru) 2006-01-20
KR20050085934A (ko) 2005-08-29
JP2006512373A (ja) 2006-04-13
IL169489A0 (en) 2007-07-04
JP4880223B2 (ja) 2012-02-22
CA2512187A1 (en) 2004-07-15
EP1582209A1 (en) 2005-10-05
EP1582209A4 (en) 2010-02-10
AU2003292876A1 (en) 2004-07-22
EP1582209B1 (en) 2012-09-19
CN101015648B (zh) 2010-05-26
CN1731991A (zh) 2006-02-08
CN100413496C (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
CN103945848B (zh) 被取代的喹唑啉酮的口服即释制剂
Gould et al. Nicotine enhancement of contextual fear conditioning
BRPI0416216A (pt) composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
MX2007011031A (es) Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
BR0317217A (pt) Uso de derivados de ésteres de succinato para a produção de medicamentos e composição farmacêutica
Aljuffali et al. The codrug approach for facilitating drug delivery and bioactivity
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
BR0016935A (pt) Uso de derivados de ácido fumárico para tratamento de doenças mitocondriais
NO903911L (no) Fremgangsmaate for fremstilling av 4-hydroksytetrahydropyran-2-on og de tilsvarende dihydroksykarboksylsyrederivater, salter og estere, deres anvendelse som legemidler, farmasoeytiske og forprodukter.
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AU2001293858A1 (en) Immunomodulatory protein derived from the yaba monkey tumor virus
EA200100568A1 (ru) Фармацевтические композиции в капсулах из гидроксипропилметилцеллюлозы
Shinmei et al. Effect of Brazilian propolis on scratching behavior induced by compound 48/80 and histamine in mice
Norris Flush‐Free Niacin”: Dietary Supplement May Be “Benefit‐Free
HUP9903410A2 (hu) Tolfenámsavat vagy gyógyszerészetileg elfogadható sóját tartalmazó, gyors hatóanyag-leadású tabletta
Gao et al. Synthesis and biological evaluation of the codrug of Leonurine and Aspirin as cardioprotective agents
Katunuma et al. Catechin derivatives: specific inhibitor for caspases-3, 7 and 2, and the prevention of apoptosis at the cell and animal levels
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
ES2674996T3 (es) Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de los mismos
BRPI0410703A (pt) compostos úteis na terapia da doença de alzheimer e formulações contendo os mesmos
BR0016235A (pt) Derivados heterocìclicos
CN107205978B (zh) 制剂及其制备方法和应用
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
Vaglini et al. Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity in mice

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DA RPI 2316 DE 26/05/2015 POR TER SIDO INDEVIDA, VISTO QUE, CONFORME INFORMADO ATRAVES DO OFICIO NO 212/2015-COOPI/SUMED/ANVISA, DE 01/06/2015, O MESMO AINDA ENCONTRA-SE EM FASE DE RECURSO NA ANVISA.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements